NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis

IDEAYA Biosciences, Inc. (IDYA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IDYA

$39.86

−$0.11 (−0.28%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IDYA with… →

IDYA Key Statistics

As of Sep 4, 2026
Trading
Open
$39.55
Previous Close
$39.97
Day's Range
39.42–40.07
52-Week Range
23.23–42.68
Volume
447.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.08
Valuation
Market Cap
$3.85B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
16.43
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.92
Financials (FY)
Revenue (FY)
$218.71M+3024.43%
Net Income (FY)
−$113.70M
Profit marginThe share of revenue left as profit after all costs and taxes.
−74.75%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
96.49M
1-Year Return
+54.32%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
1.08M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IDYA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+15.30%
2025+34.51%
2024−27.77%
2023+95.82%
2022−23.14%
2021+68.86%
2020+86.67%
2019 (partial year)−32.98%

As of September 4, 2026.

IDYA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$218.71M−$113.70M−52.0%
2024$7.00M−$274.48M−3921.1%
2023$23.39M−$112.96M−483.0%
2022$50.93M−$58.66M−115.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$218.71M—−$159.31M−$113.70M−52.0%
2024$7.00M—−$326.98M−$274.48M−3921.1%
2023$23.39M—−$134.43M−$112.96M−483.0%
2022$50.93M—−$62.50M−$58.66M−115.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IDYA Valuation vs Biotechnology Median

Median of 656 stocks
MetricIDYABiotechnology medianvs median
P/S ratio16.4315.268% above
Profit margin−74.75%0.00%74.8 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

IDEAYA Biosciences, Inc. (IDYA) carries a market capitalisation of $3.85B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 145 employees.

Over the past 52 weeks the price has ranged from $23.23 to $42.68. IDYA last closed at $39.86 on September 4, 2026. That is −$0.11 (−0.28%) against the previous close. The latest close sits 71.59% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $218.71M. That is +3,024.43% against the prior fiscal year, when revenue was $7.00M. The same year closed with a net loss of $113.70M. Profit margin runs at −74.75%. That is 74.8 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −1.92.

Across the 4 fiscal years on file, revenue moves from $50.93M in 2022 to $218.71M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 16.43. On price-to-sales that is 7.62% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is −0.08. Daily returns over the trailing 7 years annualize to a volatility of 73.76%. The trailing one-year price return is +54.32%. Measured over 5 years, that is +9.95% a year compounded.

Growth & Income

No dividend is on file for IDYA.

Across the complete calendar years on file, 2023 returned +95.82% and 2024 returned −27.77%. Of the 6 complete calendar years on file, 4 finished higher. So far in 2026 the price is +15.30%.

Peer Comparison

IDEAYA Biosciences, Inc. (IDYA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
IDEAYA Biosciences, Inc. IDYA $3.85B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. IDEAYA Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Visit website →